Research programme: tetracosactide - Retrophin

Drug Profile

Research programme: tetracosactide - Retrophin

Alternative Names: 1-24-Corticotropin - Retrophin; ACTH (1-24) -Retrophin; Cosyntropin - Retrophin; RE-034

Latest Information Update: 19 May 2016

Price : $50

At a glance

  • Originator Retrophin
  • Class Corticosteroids; Melanocortins; Peptides
  • Mechanism of Action Melanocortin receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Infantile spasms; Nephrotic syndrome

Most Recent Events

  • 03 May 2016 Preclinical development of RE 034 is ongoing in USA
  • 05 Mar 2015 Retrophin files for a provisional patent protection with US PTO for a novel formulation of RE 034 in USA
  • 05 Mar 2015 RE 034 is still in preclinical trials for multiple rare indications in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top